{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:01:00Z","timestamp":1761948060059},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T00:00:00Z","timestamp":1438992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s10198-015-0716-7","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T04:20:38Z","timestamp":1438921238000},"page":"711-721","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Health resource utilization associated with skeletal-related events: results from a retrospective European study"],"prefix":"10.1007","volume":"17","author":[{"given":"Jean-Jacques","family":"Body","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Harm","family":"Sleeboom","sequence":"additional","affiliation":[]},{"given":"Nikos","family":"Maniadakis","sequence":"additional","affiliation":[]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[]},{"given":"Yves Pascal","family":"Acklin","sequence":"additional","affiliation":[]},{"given":"Jindrich","family":"Finek","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"Gunther","sequence":"additional","affiliation":[]},{"given":"Guy","family":"Hechmati","sequence":"additional","affiliation":[]},{"given":"Tony","family":"Mossman","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Wojciech","family":"Rogowski","sequence":"additional","affiliation":[]},{"given":"Hareth","family":"Nahi","sequence":"additional","affiliation":[]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,8,8]]},"reference":[{"issue":"3","key":"716_CR1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O\u2019Sullivan, J.M., Fossa, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D.C., Hoskin, P., Bottomley, D., James, N.D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall\u2019Oglio, M., Franzen, L., Coleman, R., Vogelzang, N.J., O\u2019Bryan-Tear, C.G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, O.S., Sartor, O., Investigators, A.: Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369(3), 213\u2013223 (2013). doi: 10.1056\/NEJMoa1213755","journal-title":"N. Engl. J. Med."},{"issue":"20 Pt 2","key":"716_CR2","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman, R.E.: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s\u20136249s (2006). doi: 10.1158\/1078-0432.CCR-06-0931","journal-title":"Clin. Cancer Res."},{"issue":"8 Suppl","key":"716_CR3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman, R.E.: Skeletal complications of malignancy. Cancer 80(8 Suppl), 1588\u20131594 (1997). doi: 10.1002\/(SICI)1097-0142(19971015)80","journal-title":"Cancer"},{"issue":"8","key":"716_CR4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","volume":"16","author":"L Costa","year":"2008","unstructured":"Costa, L., Badia, X., Chow, E., Lipton, A., Wardley, A.: Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence. Support. Care Cancer 16(8), 879\u2013889 (2008). doi: 10.1007\/s00520-008-0418-0","journal-title":"Support. Care Cancer"},{"issue":"1","key":"716_CR5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M Norgaard","year":"2010","unstructured":"Norgaard, M., Jensen, A.O., Jacobsen, J.B., Cetin, K., Fryzek, J.P., Sorensen, H.T.: Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J. Urol. 184(1), 162\u2013167 (2010). doi: 10.1016\/j.juro.2010.03.034","journal-title":"J. Urol."},{"issue":"8","key":"716_CR6","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad, F., Lipton, A., Cook, R., Chen, Y.M., Smith, M., Coleman, R.: Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110(8), 1860\u20131867 (2007). doi: 10.1002\/cncr.22991","journal-title":"Cancer"},{"issue":"1","key":"716_CR7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-011-1721-x","volume":"131","author":"N Sathiakumar","year":"2012","unstructured":"Sathiakumar, N., Delzell, E., Morrisey, M.A., Falkson, C., Yong, M., Chia, V., Blackburn, J., Arora, T., Brill, I., Kilgore, M.L.: Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res. Treat. 131(1), 231\u2013238 (2012). doi: 10.1007\/s10549-011-1721-x","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"716_CR8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jval.2010.11.014","volume":"14","author":"J Felix","year":"2011","unstructured":"Felix, J., Andreozzi, V., Soares, M., Borrego, P., Gervasio, H., Moreira, A., Costa, L., Marcelo, F., Peralta, F., Furtado, I., Pina, F., Albuquerque, C., Santos, A., Passos-Coelho, J.L.: Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health. 14(4), 499\u2013505 (2011). doi: 10.1016\/j.jval.2010.11.014","journal-title":"Value Health."},{"key":"716_CR9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cmonc.2012.02.015","volume":"9","author":"A Mahmood","year":"2012","unstructured":"Mahmood, A., Ghazal, H., Fink, M.G., Patel, M., Atchison, C., Wei, R., Suenaert, P., Pinzone, J.J., Slasor, P., Chung, K.: Health-resource utilization attributable to skeletal-related events in patients with advanced cancers associated with bone metastases: results of the US cohort from a multicenter observational study. Comm. Oncol. 9, 148\u2013157 (2012)","journal-title":"Comm. Oncol."},{"issue":"6","key":"716_CR10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2354.2009.01135.x","volume":"19","author":"RD Pockett","year":"2010","unstructured":"Pockett, R.D., Castellano, D., McEwan, P., Oglesby, A., Barber, B.L., Chung, K.: The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur. J. Cancer Care (Engl.) 19(6), 755\u2013760 (2010). doi: 10.1111\/j.1365-2354.2009.01135.x","journal-title":"Eur. J. Cancer Care (Engl.)"},{"issue":"3","key":"716_CR11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0302-2838(03)00007-1","volume":"43","author":"MT Groot","year":"2003","unstructured":"Groot, M.T., Boeken Kruger, C.G., Pelger, R.C., Uyl-de Groot, C.A.: Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur. Urol. 43(3), 226\u2013232 (2003). doi: 10.1016\/S0302-2838(03)00007-1","journal-title":"Eur. Urol."},{"issue":"7","key":"716_CR12","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdl093","volume":"17","author":"M Botteman","year":"2006","unstructured":"Botteman, M., Barghout, V., Stephens, J., Hay, J., Brandman, J., Aapro, M.: Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann. Oncol. 17(7), 1072\u20131082 (2006). doi: 10.1093\/annonc\/mdl093","journal-title":"Ann. Oncol."},{"issue":"7","key":"716_CR13","first-page":"341","volume":"4","author":"T Delea","year":"2006","unstructured":"Delea, T., McKiernan, J., Brandman, J., Edelsberg, J., Sung, J., Raut, M., Oster, G.: Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J. Support. Oncol. 4(7), 341\u2013347 (2006)","journal-title":"J. Support. Oncol."},{"issue":"5","key":"716_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3111\/13696998.2013.779921","volume":"16","author":"G Hechmati","year":"2013","unstructured":"Hechmati, G., Cure, S., Gouepo, A., Hoefeler, H., Lorusso, V., Luftner, D., Duran, I., Garzon-Rodriguez, C., Ashcroft, J., Wei, R., Ghelani, P., Bahl, A.: Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J. Med. Econ. 16(5), 69\u2013700 (2013). doi: 10.3111\/13696998.2013.779921","journal-title":"J. Med. Econ."},{"issue":"2","key":"716_CR15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jbo.2014.04.001","volume":"3","author":"H Hoefeler","year":"2014","unstructured":"Hoefeler, H., Duran, I., Hechmati, G., Garzon Rodriguez, C., L\u00fcftner, D., Ashcroft, J., Bahl, A., Atchison, C., Wei, R., Thomas, E., Lorusso, V.: Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective\u2013\u2013prospective observational study\u2013\u2013a cohort from 4 European countries. J. Bone Oncol. 3(2), 40\u201348 (2014)","journal-title":"J. Bone Oncol."},{"issue":"10","key":"716_CR16","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1007\/s00259-008-0841-y","volume":"35","author":"L Bodei","year":"2008","unstructured":"Bodei, L., Lam, M., Chiesa, C., Flux, G., Brans, B., Chiti, A., Giammarile, F.: EANM procedure guideline for treatment of refractory metastatic bone pain. Eur. J. Nucl. Med. Mol. Imaging 35(10), 1934\u20131940 (2008). doi: 10.1007\/s00259-008-0841-y","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"716_CR17","author":"R Coleman","year":"2014","unstructured":"Coleman, R., Body, J.J., Aapro, M., Hadji, P., Herrstedt, J., on behalf of the, E.G.W.G: Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. (2014). doi: 10.1093\/annonc\/mdu103","journal-title":"Ann. Oncol."},{"issue":"4","key":"716_CR18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00520-006-0161-3","volume":"15","author":"NM Bradley","year":"2007","unstructured":"Bradley, N.M., Husted, J., Sey, M.S., Husain, A.F., Sinclair, E., Harris, K., Chow, E.: Review of patterns of practice and patients\u2019 preferences in the treatment of bone metastases with palliative radiotherapy. Support. Care Cancer 15(4), 373\u2013385 (2007). doi: 10.1007\/s00520-006-0161-3","journal-title":"Support. Care Cancer"},{"key":"716_CR19","doi-asserted-by":"crossref","unstructured":"Sze, W.M., Shelley, M., Held, I., Mason, M.: Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy\u2014a systematic review of the randomised trials. Cochrane Database Syst. Rev.(2), Cd004721 (2004). doi: 10.1002\/14651858.cd004721","DOI":"10.1002\/14651858.CD004721"},{"issue":"1","key":"716_CR20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.2000.18.1.72","volume":"18","author":"BE Hillner","year":"2000","unstructured":"Hillner, B.E., Weeks, J.C., Desch, C.E., Smith, T.J.: Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 18(1), 72\u201379 (2000)","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"716_CR21","first-page":"317","volume":"14","author":"MJ Lage","year":"2008","unstructured":"Lage, M.J., Barber, B.L., Harrison, D.J., Jun, S.: The cost of treating skeletal-related events in patients with prostate cancer. Am. J. Manag. Care 14(5), 317\u2013322 (2008)","journal-title":"Am. J. Manag. Care"},{"issue":"Suppl 7","key":"716_CR22","doi-asserted-by":"crossref","first-page":"vii11","DOI":"10.1093\/annonc\/mds232","volume":"23","author":"F Cardoso","year":"2012","unstructured":"Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., Senkus, E., Group E.G.W: Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii11\u2013vii19 (2012). doi: 10.1093\/annonc\/mds232","journal-title":"Ann. Oncol."},{"issue":"Suppl 7","key":"716_CR23","doi-asserted-by":"crossref","first-page":"vii65","DOI":"10.1093\/annonc\/mds227","volume":"23","author":"B Escudier","year":"2012","unstructured":"Escudier, B., Eisen, T., Porta, C., Patard, J.J., Khoo, V., Algaba, F., Mulders, P., Kataja, V., Group E.G.W: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii65\u2013vii71 (2012). doi: 10.1093\/annonc\/mds227","journal-title":"Ann. Oncol."},{"issue":"Suppl 6","key":"716_CR24","doi-asserted-by":"crossref","first-page":"vi106","DOI":"10.1093\/annonc\/mdt208","volume":"24","author":"A Horwich","year":"2013","unstructured":"Horwich, A., Parker, C., de Reijke, T., Kataja, V., Group E.G.W: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl 6), vi106\u2013vi114 (2013). doi: 10.1093\/annonc\/mdt208","journal-title":"Ann. Oncol."},{"key":"716_CR25","unstructured":"Mottet, N., Bastian, P.J., Bellmunt, J., van den Bergh, R.C.N., Bolla, M., van Casteren, N.J., Cornford, P., Joniau, S., Mason, M.D., Matveev, V., van der Kwast, T.H., van der Poel, H., Rouvi\u00e8re, O., Wiegel, T.: EAU Clinical guidelines: Guidelines on Prostate Cancer. (2014). Accessed 27 May 2014"},{"issue":"Suppl 7","key":"716_CR26","doi-asserted-by":"crossref","first-page":"vii56","DOI":"10.1093\/annonc\/mds226","volume":"23","author":"S Peters","year":"2012","unstructured":"Peters, S., Adjei, A.A., Gridelli, C., Reck, M., Kerr, K., Felip, E., Group E.G.W: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii56\u2013vii64 (2012). doi: 10.1093\/annonc\/mds226","journal-title":"Ann. Oncol."},{"issue":"9","key":"716_CR27","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body, J.J., Diel, I.J., Lichinitser, M.R., Kreuser, E.D., Dornoff, W., Gorbunova, V.A., Budde, M., Bergstrom, B.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14(9), 1399\u20131405 (2003)","journal-title":"Ann. Oncol."},{"issue":"3","key":"716_CR28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault, R.L., Lipton, A., Hortobagyi, G.N., Leff, R., Gluck, S., Stewart, J.F., Costello, S., Kennedy, I., Simeone, J., Seaman, J.J., Knight, R.D., Mellars, K., Heffernan, M., Reitsma, D.J.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J. Clin. Oncol. 17(3), 846\u2013854 (1999)","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"716_CR29","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J.L., Vinholes, J.J., Goas, J.A., Zheng, M.: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96(11), 879\u2013882 (2004)","journal-title":"J. Natl Cancer Inst."},{"issue":"1","key":"716_CR30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","volume":"15","author":"P Barrett-Lee","year":"2014","unstructured":"Barrett-Lee, P., Casbard, A., Abraham, J., Hood, K., Coleman, R., Simmonds, P., Timmins, H., Wheatley, D., Grieve, R., Griffiths, G., Murray, N.: Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 15(1), 114\u2013122 (2014). doi: 10.1016\/s1470-2045(13)70539-4","journal-title":"Lancet Oncol."},{"issue":"2","key":"716_CR31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CBC.2005.n.014","volume":"6","author":"DH Gordon","year":"2005","unstructured":"Gordon, D.H.: Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clin. Breast Cancer 6(2), 125\u2013131 (2005). doi: 10.3816\/CBC.2005.n.014","journal-title":"Clin. Breast Cancer"},{"issue":"9768","key":"716_CR32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., Jiang, Q., Tadros, S., Dansey, R., Goessl, C.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768), 813\u2013822 (2011). doi: 10.1016\/s0140-6736(10)62344-6","journal-title":"Lancet"},{"issue":"3","key":"716_CR33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V., Costa, L., Woll, P.J., Scagliotti, G., Smith, G., Feng, A., Jun, S., Dansey, R., Yeh, H.: Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support. Care Cancer 22(3), 679\u2013687 (2014). doi: 10.1007\/s00520-013-2022-1","journal-title":"Support. Care Cancer"},{"issue":"16","key":"716_CR34","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton, A., Fizazi, K., Stopeck, A.T., Henry, D.H., Brown, J.E., Yardley, D.A., Richardson, G.E., Siena, S., Maroto, P., Clemens, M., Bilynskyy, B., Charu, V., Beuzeboc, P., Rader, M., Viniegra, M., Saad, F., Ke, C., Braun, A., Jun, S.: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur. J. Cancer 48(16), 3082\u20133092 (2012). doi: 10.1016\/j.ejca.2012.08.002","journal-title":"Eur. J. Cancer"},{"issue":"9810","key":"716_CR35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith, M.R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damiao, R., Tammela, T.L., Egerdie, B., Van Poppel, H., Chin, J., Morote, J., Gomez-Veiga, F., Borkowski, T., Ye, Z., Kupic, A., Dansey, R., Goessl, C.: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810), 39\u201346 (2012). doi: 10.1016\/s0140-6736(11)61226-9","journal-title":"Lancet"},{"issue":"35","key":"716_CR36","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., Fan, M., Jiang, Q., Dansey, R., Jun, S., Braun, A.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28(35), 5132\u20135139 (2010). doi: 10.1200\/jco.2010.29.7101","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"716_CR37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/07357907.2010.483508","volume":"28","author":"NS Tchekmedyian","year":"2010","unstructured":"Tchekmedyian, N.S., Chen, Y.M., Saad, F.: Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors. Cancer Invest. 28(8), 849\u2013855 (2010). doi: 10.3109\/07357907.2010.483508","journal-title":"Cancer Invest."},{"issue":"Suppl. 1","key":"716_CR38","first-page":"S88","volume":"20","author":"A Casas","year":"2012","unstructured":"Casas, A., Lebret, T., Cavo, M., Woll, P.J., Deleplace, C., Kennedy, C., Jackisch, C.: Insights into the management of bone metastases: a comprehensive European survey. Support. Care Cancer 20(Suppl. 1), S88 (2012)","journal-title":"Support. Care Cancer"},{"issue":"1","key":"716_CR39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen, L.S., Gordon, D.H., Dugan Jr, W., Major, P., Eisenberg, P.D., Provencher, L., Kaminski, M., Simeone, J., Seaman, J., Chen, B.L., Coleman, R.E.: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100(1), 36\u201343 (2004). doi: 10.1002\/cncr.11892","journal-title":"Cancer"},{"issue":"2","key":"716_CR40","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","volume":"26","author":"MR Smith","year":"2015","unstructured":"Smith, M.R., Coleman, R.E., Klotz, L., Pittman, K., Milecki, P., Ng, S., Chi, K.N., Balakumaran, A., Wei, R., Wang, H., Braun, A., Fizazi, K.: Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann. Oncol. 26(2), 368\u2013374 (2015). doi: 10.1093\/annonc\/mdu519","journal-title":"Ann. Oncol."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-015-0716-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-015-0716-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-015-0716-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T04:04:43Z","timestamp":1567051483000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-015-0716-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,8]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1007\/s10198-015-0716-7","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,8]]}}}